therapeut
vaccin
cancer
import
approach
combin
therapi
improv
longterm
control
cancer
fact
induct
adapt
immun
respons
tumor
associ
antigen
taa
well
innat
immun
import
factor
tumor
stabilizationerad
varieti
immun
technolog
explor
last
decad
current
activ
evalu
cellbas
protein
peptid
heatshock
proteinbas
cancer
vaccin
genet
vaccin
emerg
promis
methodolog
elicit
immun
respons
wide
varieti
antigen
includ
taa
amongst
adenoviru
ad
base
vector
show
excel
immunogen
profil
achiev
immunolog
proof
concept
human
vivo
electropor
plasmid
dna
dnaep
also
desir
vaccin
technolog
cancer
vaccin
repeat
sever
time
paramet
requir
longterm
mainten
antitumor
immun
recent
find
show
combin
differ
modal
immun
heterolog
primeboost
abl
induc
superior
immun
reaction
compar
singlemod
vaccin
review
discuss
challeng
requir
emerg
cancer
vaccin
particularli
focus
genet
cancer
vaccin
current
activ
develop
promis
shown
ad
dnaep
heterolog
primeboost
spite
signific
progress
recent
year
toward
develop
new
target
therapi
cancer
remain
larg
unmet
medic
need
lead
caus
death
industri
countri
incid
cancer
continu
increas
often
associ
varieti
factor
includ
genet
predisposit
infecti
agent
exposur
mutagen
well
lifestyl
factor
cancer
link
occurr
genet
epigenet
chang
tumor
cell
harbor
hundr
modif
fact
also
demonstr
introduct
high
throughput
sequenc
analyz
cancer
genom
accumul
sever
genet
chang
result
express
sever
modifi
gene
product
tumor
growth
impli
cancer
cell
recogn
foreign
entiti
potenti
elimin
immun
system
basi
theori
immunosurveil
notwithstand
cancer
immunotherapi
seen
mani
clinic
failur
success
howev
recent
major
breakthrough
achiev
led
us
believ
approach
may
becom
establish
therapeut
modal
treatment
cancer
within
next
decad
matter
fact
import
cancer
vaccin
recent
increas
follow
demonstr
sipuleucelt
immun
cellbas
vaccin
treatment
hormon
refractori
prostat
cancer
capabl
extend
overal
surviv
cancer
patient
lead
fda
approv
cancer
vaccin
name
proveng
dendreon
approv
propel
renew
enthusiasm
area
long
suffer
major
setback
review
focu
mainli
variou
technolog
util
therapeut
cancer
vaccin
provid
updat
advanc
clinic
develop
major
emphasi
given
adenovir
vector
dna
electropor
reader
interest
detail
descript
cancer
immunolog
immunotherapi
suggest
recent
excel
review
palucka
et
al
klebanoff
et
al
differ
technolog
employ
develop
cancer
vaccin
review
divid
two
main
categori
non
genet
vaccin
genet
vaccin
main
advantag
genet
vaccin
allow
endogen
express
antigen
interest
muscl
andor
antigenpres
cell
maxim
antigen
process
endogen
pathway
epitop
display
mhc
class
molecul
b
appropri
molecular
engin
target
tumor
antigen
help
significantli
boost
selfantigen
immunogen
break
toler
review
detail
individu
technolog
current
progress
would
like
stress
guid
concept
therapeut
cancer
vaccin
develop
ideal
cancer
vaccin
administ
prolong
period
time
possibl
chronic
treatment
without
loss
immunogen
cancer
vaccin
aim
break
toler
selfantigen
toler
broken
vaccin
discontinu
selfrespons
tend
vane
due
presenc
mechan
toler
henc
necessari
sustain
selfimmunogen
tumor
antigen
order
induc
protect
immun
respons
effici
helperctl
activ
longterm
immunolog
memori
goal
similar
mani
infecti
diseas
potenti
achiev
long
term
antitumor
efficaci
figur
concept
demonstr
varieti
preclin
model
appli
cancer
vaccin
human
clinic
trial
whole
cell
vaccin
perhap
oldest
approach
util
irradi
cancer
cell
either
autolog
allogen
sourc
tumor
antigen
either
combin
adjuv
genet
modifi
shown
induc
tumorspecif
immun
durabl
antitumor
respons
number
phase
ii
trial
howev
past
year
sever
highprofil
phase
iii
trial
includ
conduct
use
promis
gvax
technolog
see
fail
meet
predefin
endpoint
mechan
action
type
vaccin
crosspresent
cellderiv
taa
specif
cytotox
lymphocyt
ctl
vivo
crossprim
facilit
dendrit
cell
dc
activ
adjuv
cytokin
gmcsf
advanc
autolog
vaccin
mvax
avax
technolog
oncovax
vaccinogen
renial
vcc
medic
bv
phase
iii
clinic
trial
melanoma
colorect
renal
cancer
respect
case
mvax
autolog
tumor
cell
modifi
dnp
readminist
patient
case
oncovax
irradi
patientspecif
tumor
cell
sadmix
frozen
bacillu
calmetteguerin
bcg
adjuv
advantag
use
allogen
cell
obviou
util
antigen
welldefin
cell
line
provid
access
sustain
virtual
unlimit
sourc
taa
use
cell
line
allow
highli
standard
largescal
product
vaccin
use
singl
batch
allovaccin
vaccine
regardless
hla
haplotyp
elimin
variabl
qualiti
composit
vaccin
facilit
reliabl
compar
analysi
clinic
outcom
elimin
need
continu
product
tailormad
individu
vaccin
simplifi
logist
reduc
labori
vaccin
product
deliveri
process
thu
increment
costeffect
gvax
technolog
tumor
cell
transduc
gmcsf
mention
previou
phase
iii
trial
gvax
fail
meet
clinic
endpoint
howev
biosant
pharmaceut
inc
recent
restart
develop
gvax
phase
ii
trial
prostat
cancer
patient
support
part
prostat
cancer
foundat
addit
allogen
vaccin
hyperacut
pancrea
newlink
genet
corpor
lucanix
novarx
corpor
lucanix
consist
four
nonsmal
cell
lung
cancer
cell
line
genemodifi
block
cytokin
known
inhibit
immun
respons
cancer
hyperacut
pancrea
mixtur
irradi
allogen
cell
genet
modifi
express
galactosyl
residu
link
cellsurfac
lipid
protein
epitop
believ
work
exploit
natur
presenc
antig
antibodi
induc
tumor
recognit
opson
uptak
apc
canvaxin
cancervax
anoth
whole
cell
vaccin
approach
enter
phase
iii
test
allogen
melanoma
vaccin
irradi
cell
melanoma
cell
line
given
intraderm
bcg
nonrandom
phase
ii
studi
patient
stage
iiiaiv
melanoma
median
os
month
compar
month
histor
control
surviv
correl
vaccin
dth
respons
antibodi
induct
sever
studi
howev
canvaxin
demonstr
efficaci
phase
iii
studi
postsurg
adjuv
treatment
patient
advancedstag
melanoma
compani
announc
discontinu
immun
cellbas
vaccin
sipuleucelt
advanc
patientspecif
whole
cell
vaccin
util
least
part
profession
antigen
present
cell
apc
isol
patient
manipul
vitro
present
tumor
antigen
choic
deliv
featur
facilit
home
secondari
lymphoid
organ
thu
induc
respons
apc
eg
dc
load
tumor
antigen
form
peptid
protein
tumor
lysat
mrna
altern
fuse
tumor
cell
infect
viral
vector
encod
tumorassoci
antigen
prepar
product
like
sipuleucelt
initi
involv
leukapheresi
obtain
peripher
blood
patient
leukapheres
specimen
transfer
compani
manufactur
facil
cell
pellet
contain
apc
predominantli
lymphocyt
b
lymphocyt
monocyt
natur
killer
cell
expos
engin
antigencytokin
fusion
protein
consist
pap
prostat
acid
protein
gmcsf
gmcsf
facilit
uptak
fusion
protein
dc
promot
dc
stimul
pap
tumor
antigen
use
vaccin
approach
final
product
transport
patient
infus
intraven
within
h
formul
despit
describ
technic
complex
sipuleucelt
recent
award
food
drug
administr
fda
approv
base
success
phase
iii
trial
show
improv
overal
surviv
os
men
asymptomat
minim
symptomat
metastat
advanc
castrat
resist
prostat
cancer
crpc
sever
featur
clinic
develop
dcand
immun
cellbas
cancer
vaccin
bear
sever
featur
make
technolog
ideal
larg
scale
applic
first
aspect
difficulti
set
standard
procedur
reliabl
produc
function
apc
current
demonstr
prepar
level
process
present
antigen
activ
equival
immun
respons
administr
problemat
true
multipl
prepar
given
one
patient
differ
prepar
given
mani
patient
intrapati
interpati
variabl
qualiti
control
process
cellular
product
critic
integr
product
larg
amount
autolog
peripher
blood
mononuclear
cell
must
cultur
presenc
sever
cytokin
make
offtheshelf
market
imposs
critic
issu
ensur
proper
matur
statu
cell
also
precis
select
appropri
subset
requir
elicit
desir
respons
aspect
includ
high
manufactur
cost
huge
amount
labor
requir
produc
viabl
product
within
short
time
frame
one
assum
limit
may
also
neg
impact
upon
vaccin
efficaci
patient
inde
sever
studi
tend
suggest
optim
regimen
therapeut
vaccin
chronic
treatment
prolong
period
time
proveng
current
administ
three
dose
treatment
henc
reason
hypothes
efficaci
vaccin
would
superior
could
produc
straightforward
manner
lower
cost
thu
allow
extend
treatment
heat
shock
protein
base
vaccin
use
heat
shock
protein
hsp
peptid
complex
natur
host
vector
vaccin
heat
shock
protein
intracellular
molecul
famili
character
member
similar
molecular
mass
act
chaperon
repertoir
peptid
includ
normal
selfpeptid
antigen
peptid
protein
synthesi
breakdown
heat
shock
protein
complex
releas
cell
still
associ
noncoval
peptid
releas
necrot
cell
function
endogen
danger
signal
well
method
crosspres
antigen
dc
fact
dc
specif
receptor
heat
shock
protein
engag
lead
matur
hsp
complex
antigen
peptid
shown
effici
deliv
peptid
mhc
class
process
pathway
thu
gener
cellular
immun
respons
immunogen
tumorderiv
hsppeptid
complex
like
immunogen
experiment
induc
tumor
mice
rat
shown
individu
tumorspecif
tumor
type
specif
observ
led
conclus
relev
tumorantigen
immunoprotect
peptid
deriv
uniqu
rather
share
tumor
antigen
tumor
specif
hspcomplex
vaccin
name
hsp
peptid
oncophag
prophag
previous
vitespen
agenu
lexington
usa
shown
capabl
induc
mhc
irestrict
immun
respons
rang
tumor
type
clinic
respons
patient
earlierstag
diseas
line
previous
publish
data
cancer
vaccin
vitespen
almost
devoid
side
effect
asid
minor
injectionsit
reaction
howev
test
phase
iii
trial
kidney
cancer
fail
meet
predefin
endpoint
registr
ema
nevertheless
approv
russia
oncophag
adjuv
treatment
kidney
cancer
patient
intermedi
risk
diseas
recurr
current
agenu
conduct
trial
oncophag
recurr
newli
diagnos
glioblastoma
addit
approach
peptid
base
vaccin
conceiv
decad
ago
follow
identif
wealth
epitop
sever
tumor
antigen
mainli
studi
melanoma
peptid
synthes
standard
manner
cost
product
rel
low
thu
make
peptid
vaccin
technolog
choic
number
group
despit
convinc
rational
promis
preclin
result
frequent
induct
antigenspecif
immun
respons
peptidebas
cancer
vaccin
yield
rel
poor
result
clinic
set
result
phase
iii
clinic
trial
metastat
melanoma
patient
deserv
particular
mention
compar
efficaci
peptid
vaccin
fulli
human
anti
antibodi
ipilimumab
combin
agent
compar
alon
ipilimumab
improv
median
overal
surviv
month
hazard
ratio
death
p
importantli
differ
surviv
detect
ipilimumab
alon
versu
ipilimumab
plu
vaccin
group
median
overal
surviv
versu
month
hazard
ratio
ipilumumab
plu
p
base
result
ipilimumab
vaccin
recent
approv
fda
treatment
unresect
stage
iii
iv
melanoma
name
yervoy
bristolmy
squibb
one
possibl
interpret
lack
efficaci
peptid
vaccin
patient
popul
otherwis
respons
immunotherapi
necess
gener
polyclon
immun
respons
direct
simultan
sever
mhc
class
epitop
could
achiev
clinic
trial
cite
made
use
singleepitop
peptid
spite
huge
limit
singl
peptid
vaccin
still
advanc
clinic
develop
case
stimuvax
stimuvax
otherwis
call
liposom
vaccin
merck
seronooncothyreon
liposomeencapsul
peptid
vaccin
consist
synthet
peptid
deriv
mucin
antigen
overexpress
cell
surfac
mani
epitheli
tumor
cell
well
surfac
bcell
lymphoma
multipl
myeloma
cell
advanc
develop
treatment
nsclc
two
phase
iii
trial
name
start
inspir
kaelgemvax
peptid
vaccin
repres
htert
sequenc
order
overcom
limit
singl
epitop
vaccin
altern
approach
undertaken
make
use
either
combin
immunogen
peptid
synthet
longpeptid
vaccin
case
presenc
multipl
epitop
abl
elicit
polyspecif
memori
respons
tumor
cell
one
exampl
eastern
cooper
oncolog
group
phase
ii
trial
mix
peptid
contain
multipl
epitop
deriv
three
lineagerestrict
antigen
tyrosinas
administ
patient
metastat
unresect
melanoma
combin
gmcsf
note
median
overal
surviv
patient
vaccin
immun
respons
significantli
longer
patient
immun
respons
versu
month
p
recent
interest
result
phase
ii
studi
obtain
immat
cancer
patient
vaccin
multipl
tumorassoci
peptid
tumap
isol
tumor
specimen
identifi
mass
spectrometri
advanc
product
combin
sever
tumap
treatment
renal
cell
carcinoma
complet
europewid
multicent
phase
ii
clinic
trial
recent
commenc
phase
iii
trial
isol
recombin
protein
success
employ
antivir
vaccin
howev
solubl
protein
poorli
immunogen
requir
appropri
adjuv
deliveri
system
induc
immun
respons
follow
immun
optim
perform
antigen
deliveri
vehicl
close
mimic
composit
immunolog
process
actual
pathogen
activ
passiv
target
apc
dc
protect
antigen
protein
degrad
direct
natur
result
immun
respons
ie
cellular
versu
humor
respons
lastli
induc
apc
matur
interact
element
innat
immun
system
tolllik
receptor
tlr
sever
strategi
report
includ
directli
conjug
tlr
ligand
protein
antigen
coencapsul
immunostimulatori
agent
protein
liposom
hydrophob
polymer
particl
advanc
product
type
pursu
develop
antigen
specif
immunotherapi
asci
asci
therapeut
cancer
vaccin
direct
tumor
antigen
overexpress
subset
patient
affect
variou
cancer
develop
glaxosmithklin
gsk
vaccin
deliv
highli
purifi
recombin
protein
conjunct
gsk
proprietari
adjuv
system
advanc
develop
vaccin
phase
iii
trial
call
magrit
adjuv
nonsmal
cell
lung
cancer
immunotherapi
began
octob
aim
recruit
patient
random
asci
placebo
object
magrit
trial
investig
efficaci
asci
prevent
cancer
relaps
administ
tumor
resect
patient
posit
stage
ib
ii
iiia
nsclc
go
largestev
trial
adjuv
treatment
nsclc
summar
section
vaccin
gave
rise
statist
signific
surviv
benefit
phase
iii
registr
trial
far
util
immun
cellbas
approach
sever
technolog
pursu
search
viabl
altern
capabl
combin
improv
efficaci
streamlin
product
process
lower
manufactur
cost
ideal
goal
obtain
nonpatientspecif
offtheshelf
product
administ
chronic
treatment
genet
vaccin
highli
promis
tool
elicit
immun
respons
wide
varieti
antigen
includ
taa
two
main
class
genet
cancer
vaccin
util
viral
vaccin
dna
plasmid
vaccin
viral
infect
result
present
virusspecif
peptid
associ
mhc
class
mhc
class
ii
surfac
infect
cell
base
phenomenon
sever
strategi
devis
use
virus
immun
vehicl
elicit
antigenspecif
immun
respons
approach
cdna
encod
one
sever
antigen
may
wildtyp
genet
engin
insert
viral
vector
result
recombin
virus
use
infect
host
select
antigen
may
express
subsequ
present
immun
system
vaccin
purpos
ideal
viral
vector
safe
respect
diseasecaus
potenti
transmiss
longterm
persist
host
enabl
effici
present
express
antigen
immun
system
prefer
exhibit
low
intrins
immunogen
administ
repeatedli
boost
relev
specif
immun
respons
often
necessari
break
immun
toler
selfantigen
tumour
antigen
dna
sequenc
insert
attenu
pox
vector
replic
mammalian
host
modifi
vaccinia
ankara
fowlpox
canarypox
vaccinia
poxviru
vv
demonstr
safe
effect
induct
potent
cellular
humor
immun
respons
sever
tumor
model
system
one
success
stori
vaccin
base
technolog
prostvacvf
bavarian
nordic
denmark
prostvacvf
vaccin
psa
includ
number
costimulatori
molecul
three
wellcharacter
costimulatori
molecul
found
synergist
ad
poxvir
system
triad
includ
design
tricom
ad
vaccinia
prime
vector
fowlpox
boost
vector
psa
encod
antigen
configur
constitut
prostvacvf
vacciniapsatricom
fowlpoxpsatricom
random
empti
vectorcontrol
doubleblind
phase
ii
studi
design
power
shortterm
end
point
progress
free
surviv
pf
fail
find
associ
vaccin
treatment
slow
diseas
progress
howev
post
studi
strong
associ
treatment
arm
increas
overal
surviv
observ
prostvacvf
vaccin
patient
still
aliv
versu
control
estim
hazard
ratio
ci
observ
differ
median
surviv
month
suggest
signific
therapeut
benefit
base
highli
encourag
data
bavarian
nordic
plan
larger
pivot
phase
iii
trial
anoth
pox
vector
base
vaccin
trovax
mva
modifi
ankara
viru
vector
develop
oxford
biomedica
oxford
uk
direct
tumor
enrich
surfac
marker
name
clinic
trial
trovax
show
good
safeti
profil
immunolog
respons
efficaci
relat
defin
biomark
strategi
fail
meet
primari
endpoint
overal
surviv
phase
iii
registr
trial
treatment
metastat
renal
cancer
trovax
current
undergo
phase
ii
clinic
trial
treatment
hormon
refractori
prostat
cancer
final
anoth
mva
vector
vaccin
develop
transgen
strasbourg
franc
incorpor
two
express
cassett
first
antigen
second
cytokin
immun
stimul
vaccin
test
breast
kidney
prostat
lung
cancer
encourag
result
phase
ii
renal
cell
carcinoma
rcc
thirtyseven
patient
progress
tumor
receiv
pfuinject
weekli
week
everi
week
progress
continu
combin
assess
includ
clinic
respons
primari
endpoint
safeti
time
treatment
failur
ttf
os
immun
respons
object
clinic
respons
occur
median
os
month
patient
month
combin
therapi
recipi
cell
respons
associ
longer
surviv
efficaci
safeti
assess
random
control
phase
iib
studi
evalu
therapeut
vaccin
adjunct
standard
chemotherapi
patient
advanc
nsclc
primari
object
studi
name
progress
free
surviv
month
least
experiment
arm
met
phase
iib
trial
transgen
identifi
subpopul
patient
particularli
benefit
treatment
chemotherapi
versu
chemotherapi
alon
subpopul
consist
patient
normal
level
activ
nk
cell
baselin
repres
assess
patient
popul
patient
phase
iib
clinic
result
demonstr
improv
clinic
outcom
patient
subpopul
statist
signific
month
increas
median
surviv
month
experiment
arm
versu
month
control
arm
respons
rate
time
progress
progress
free
surviv
data
also
confirm
identif
activ
nk
cell
appropri
predict
biomark
associ
posit
clinic
outcom
patient
nsclc
treat
combin
chemotherapi
pivot
global
control
phase
iibiii
trial
patient
advanc
stage
iv
nsclc
expect
begin
end
trial
involv
overal
recruit
patient
posit
nsclc
emerg
viral
system
vaccin
adenoviru
ad
adbas
vector
effici
vehicl
gene
deliveri
extens
character
gene
therapi
purpos
ad
vector
propag
high
yield
welldefin
product
system
readili
amen
pharmaceut
scale
product
clinic
grade
composit
featur
wellcharacter
molecular
genet
make
recombin
ad
vector
excel
candid
use
gene
therapi
vaccin
carrier
typic
product
recombin
adenovir
vector
reli
use
packag
cell
line
complement
function
adenovir
gene
product
either
delet
engin
nonfunct
figur
septemb
percept
use
ad
vector
gene
therapi
alter
patient
affect
inherit
enzym
defici
expos
via
hepat
arteri
high
dose
adenovir
vector
succumb
toxic
relat
vector
administr
concern
rais
continu
use
ad
vector
system
importantli
increas
effort
fulli
understand
toxic
today
recogn
ad
vector
suitabl
applic
offer
signific
advantag
vector
system
includ
effici
transduct
varieti
cell
type
quiescent
divid
make
optim
certain
applic
particular
includ
protocol
adjuv
effect
adenoviru
benefici
induct
strong
antigenspecif
immun
respons
adenovirus
compris
larg
famili
doublestrand
dna
virus
found
amphibian
avian
mammal
nonenvelop
icosahedr
capsid
structur
genom
size
vari
kb
contrast
retrovirus
ad
transduc
divid
nondivid
cell
without
integr
genom
host
cell
ad
dna
typic
stabl
remain
episom
eg
extrachromosom
unless
transform
tumorigenesi
occur
ad
gene
divid
express
earli
late
viral
lifecycl
among
earli
gene
protein
encod
transactiv
factor
help
regul
host
cell
cycl
addit
need
viral
replic
host
immun
modul
inhibit
host
cell
apoptosi
ad
particl
mainli
contain
three
structur
protein
hexon
penton
fiber
hexon
protein
abund
ad
contain
copi
trimer
hexon
molecul
account
total
protein
mass
viral
capsid
interact
coxsackieviru
adenoviru
receptor
car
initi
bind
step
follow
secondari
engag
integrin
coreceptor
cell
surfac
molecul
describ
process
ad
bind
intern
mhc
class
heparin
sulfat
glycosaminoglycan
adenoviru
enter
cell
escap
endosom
access
nucleu
via
microtubul
use
nuclear
pore
complex
inject
genom
ad
natur
associ
infecti
diseas
upper
respiratori
infect
conjunct
caus
liver
kidney
urinari
tract
infect
consequ
ad
success
infect
wide
varieti
cell
includ
respiratori
epitheli
cell
myoblast
macrophag
hepatocyt
glial
cell
human
ad
had
divid
six
subgroup
af
base
number
biolog
chemic
immunolog
structur
criteria
includ
hemagglutin
properti
rat
rhesu
monkey
erythrocyt
dna
homolog
restrict
enzym
cleavag
pattern
percentag
gc
content
oncogen
date
distinct
serotyp
recogn
group
subgroup
basi
hemagglutin
properti
biophys
biochem
criteria
high
immunogen
ad
recombin
larg
exclud
success
use
sustain
gene
therapi
featur
facilit
develop
vaccin
carrier
ad
vaccin
shown
induc
highest
band
tcell
respons
experiment
anim
includ
rodent
canin
primat
varieti
immunogen
deriv
number
infecti
agent
eg
virus
parasit
bacteri
pathogen
tumor
cell
includ
tumorassoci
antigen
taa
two
wellcharacter
human
subgroup
c
adenoviru
serotyp
ie
initi
wide
use
sourc
viral
backbon
major
adenovir
vector
use
gene
therapi
vaccin
develop
recent
howev
clinic
result
shown
ad
vector
base
common
human
serotyp
serotyp
may
ideal
vaccin
carrier
phase
trial
term
step
vaccin
express
antigen
human
immunodefici
viru
show
lack
efficaci
spite
vaccin
immunogen
also
indic
increas
trend
hiv
acquisit
individu
circul
neutral
antibodi
prior
vaccin
antibodi
hexon
protein
domin
neutral
respons
elicit
human
infect
ad
hexon
protein
compos
seven
short
hypervari
region
hvr
elicit
serotypespecif
immun
respons
altern
serotyp
human
nonhuman
primat
nhp
popul
lack
preexist
immun
relev
hexon
protein
vector
may
circumv
problem
encount
use
vector
human
thu
use
uncommon
ad
serotyp
bypass
issu
preexist
immun
vector
base
human
nonsubgroup
c
ad
previous
report
almost
exclus
nonvaccin
approach
ad
subgroup
b
includ
less
preval
human
popul
presenc
antibodi
block
transduct
effici
vector
ad
infect
cell
via
human
membran
complement
protein
ubiquit
express
almost
human
tissu
henc
also
abl
infect
cell
lack
car
coxaki
adenoviru
receptor
sialic
acid
shown
act
receptor
subgroup
respect
particular
propos
altern
vaccin
deliveri
low
seropreval
howev
comparison
vector
mice
nonhuman
primat
demonstr
lower
immunolog
potenc
latter
vector
similarli
two
vector
base
rare
serotyp
induc
lower
immun
nonhuman
primat
usag
nonhuman
ad
vector
elud
immun
also
propos
sever
nonhuman
ad
natur
nonpathogen
human
well
character
unlik
had
immun
nonhuman
ad
expect
preval
human
popul
shown
exampl
preexist
humor
immun
human
cross
neutral
ovin
chimpanze
canin
porcin
fowl
ad
led
engin
varieti
nonhuman
ad
vector
effici
transduc
sever
type
human
murin
cell
cultur
engin
util
receptor
cell
intern
cell
entri
often
independ
car
particular
vector
porcin
bovin
interest
preexist
anti
crossneutr
antibodi
detect
human
mice
moreov
overcom
neutral
antibodi
chimpanze
ad
chad
vector
develop
chad
vector
proven
particularli
effect
tool
vaccin
varieti
viral
antigen
diseas
influenza
caus
strain
human
immunodefici
viru
type
nhp
rabi
viru
sever
acut
respiratori
syndrom
mediat
sarscoronaviru
strategi
avoid
ad
vector
neutral
particularli
relev
use
cancer
vaccin
fact
one
major
obstacl
achiev
tumor
specif
immun
respons
overcom
central
andor
peripher
cell
toler
taa
induc
ctl
could
effect
erad
dissemin
tumor
metastas
subsequ
maintain
long
last
immunolog
memori
prevent
tumor
recurr
ad
vector
proven
efficaci
vaccin
vector
capabl
break
immun
toler
target
antigen
transgen
mice
express
human
taa
well
nonhuman
primat
importantli
chimp
ad
base
vaccin
shown
abl
induc
immun
respons
compar
serotypebas
vector
break
toler
selftumor
antigen
overcom
preexist
immun
achiev
antitumor
effect
conclus
therefor
ad
vector
constitut
vast
repertoir
agent
suitabl
develop
therapeut
cancer
vaccin
avail
multipl
serotyp
nonhuman
ad
vector
success
overcom
issu
previous
observ
base
vaccin
sever
clinic
studi
use
ad
vector
conduct
oncolog
among
other
intratumor
inject
ad
contain
wildtyp
tumor
suppressor
gene
show
clinic
efficaci
combin
chemotherapi
led
clinic
develop
advexin
gendicin
advexin
gendicin
recombin
region
replac
human
wild
type
express
cassett
contain
cytomegaloviru
cmv
rou
sarcoma
viru
rsv
promot
respect
octob
chines
state
food
drug
administr
csfda
approv
gendicin
first
commerci
gene
therapi
product
world
anoth
advanc
applic
repres
oncolyt
ad
best
known
exampl
first
engin
replicationselect
viru
use
human
hybrid
delet
region
replic
exclus
cell
inact
activ
late
viral
mrna
transport
test
clinic
trial
direct
inject
vp
result
limit
antitumor
effect
object
respons
rate
system
spread
viru
detect
one
possibl
reason
poor
result
extent
virus
infect
target
cell
mani
tumor
downregul
car
render
less
suscept
infect
novemb
csfda
approv
oncolyt
adenoviru
similar
use
combin
chemotherapi
treatment
latestag
refractori
nasopharyng
cancer
also
import
mention
oncolyt
vector
other
ad
base
one
emerg
fashion
approach
oncolyt
viru
deriv
hsv
herp
simplex
viru
activ
pursu
amgenbiovex
oncovex
gmcsf
select
infect
gener
gmcsf
tumor
cell
result
increas
tumor
antigen
present
recruit
dc
agent
present
phase
iii
trial
melanoma
head
neck
cancer
base
highli
promis
phase
ii
trial
result
specif
relat
develop
cancer
vaccin
sever
group
current
assess
immunolog
clinic
activ
ad
vector
express
varieti
taa
includ
prostat
serum
antigen
psa
carcinoembryon
antigen
cea
telomeras
htert
great
interest
verifi
local
system
suppress
exert
tumor
well
preexist
immun
ad
impact
outcom
studi
inocul
plasmid
dna
encod
protein
antigen
mean
simpl
intramuscular
intraderm
inject
current
offer
vaccin
approach
easili
perform
safe
host
rel
inexpens
dna
deliveri
vehicl
consist
gene
regul
promot
usual
show
constitut
activ
exampl
cytomegaloviru
earli
enhancerpromot
see
figur
simpl
inject
nake
dna
sequenc
result
gene
express
potenti
gener
immun
respons
possibl
mechan
dna
immun
work
follow
protein
antigen
produc
target
cell
usual
myocyt
fibroblast
depend
inject
rout
secret
antigen
may
taken
host
apc
process
crosspres
immun
system
drain
lymph
node
direct
transfect
rare
apc
resid
inject
site
also
demonstr
howev
target
cell
lack
costimulatori
molecul
need
part
ctl
activ
process
therefor
dna
vaccin
gener
poorli
effici
unless
inflammatori
stimulu
appli
parallel
plasmid
dna
abil
make
new
dna
vaccin
without
need
handl
virul
pathogen
adapt
manufactur
purpos
open
suitabl
vaccin
technolog
develop
cancer
vaccin
also
emerg
epidem
pathogen
four
anim
health
plasmid
dna
product
includ
two
prophylact
vaccin
infecti
diseas
one
immunotherapi
cancer
oncept
tm
see
one
gene
therapi
deliveri
hormon
food
anim
recent
approv
drug
administr
author
confirm
efficaci
dna
vaccin
multipl
speci
includ
also
larg
anim
dog
hors
pig
particular
mention
deserv
oncept
tm
current
first
usdaapprov
therapeut
vaccin
treatment
cancer
oncept
tm
develop
merial
partnership
memori
sloankett
center
anim
medic
center
new
york
dna
vaccin
express
human
tyrosinas
therefor
defin
xenogen
vaccin
canin
malign
melanoma
deliv
via
transderm
devic
develop
conjunct
bioject
inc
deliv
vaccin
without
use
needl
oncept
tm
shown
extend
surviv
dog
stage
ii
iii
oral
canin
melanoma
mous
model
dna
vaccin
success
direct
wide
varieti
tumor
almost
exclus
drive
strong
cellular
immun
respons
antigenspecif
fashion
howev
still
need
improv
deliveri
dna
vaccin
increas
immunogen
antigen
express
plasmid
clinic
trial
dna
vaccin
shown
immun
respons
gener
human
also
highlight
increas
potenc
requir
vaccin
technolog
effect
exampl
basi
success
use
tyrosinas
melanoma
preclin
model
sever
clinic
trial
conduct
still
ongo
initi
studi
patient
metastat
melanoma
immun
human
express
nake
plasmid
show
clinic
immunolog
respons
indic
deliveri
system
adequ
costimul
play
import
role
success
approach
xenogen
dna
vaccin
also
evalu
two
recent
phase
trial
use
mous
dna
vaccin
alon
combin
human
homologu
melanoma
patient
immun
xenogen
vaccin
develop
cell
show
immun
respons
plasmid
dna
encod
psma
use
two
phase
iii
studi
immun
patient
prostat
cancer
costimul
plasmid
dna
molecul
led
delayedtyp
hypersens
psma
half
patient
addit
boost
ad
necessari
induc
immun
howev
success
trial
difficult
interpret
due
heterogen
patient
popul
phase
iii
trial
idiotyp
vaccin
follicular
bcell
lymphoma
use
genet
approach
also
conduct
vaccin
encod
individu
dna
idiotyp
singlechain
variabl
fragment
scfv
fuse
tetanu
toxoid
fragment
c
ttfrc
deliv
nake
dna
im
inject
patient
follicular
lymphoma
clinic
remiss
follow
chemotherapi
abl
develop
cellular
orand
humor
antiidiotyp
immun
respons
patient
period
sever
month
although
reason
dna
vaccin
fail
induc
potent
effect
immun
respons
human
yet
elucid
reason
assum
low
level
antigen
product
ineffici
cellular
deliveri
dna
plasmid
importantli
insuffici
stimul
innat
immun
system
role
low
potenc
dna
vaccin
therefor
optim
dna
vaccin
strategi
necessari
order
design
better
dna
vaccin
regimen
plasmid
dose
time
dose
appropri
adjuv
deliveri
system
andor
rout
vaccin
must
taken
consider
gener
dna
plasmid
deliv
use
number
physic
approach
includ
tattoo
gene
gun
ultrasound
laser
dna
electropor
particularli
focu
attent
dna
electropor
vivo
electropor
plasmid
dna
dnaep
emerg
safe
method
result
greater
dna
uptak
lead
enhanc
protein
express
treat
muscl
concomit
increas
immun
respons
target
antigen
varieti
speci
properti
dnaep
desir
vaccin
technolog
cancer
vaccin
repeat
sever
time
requir
mainten
antitumor
immun
approach
use
brief
electr
puls
creat
transient
pore
cell
membran
thu
allow
larg
molecul
dna
rna
enter
cell
cytoplasm
immedi
follow
cessat
electr
field
pore
seal
molecul
trap
cytoplasm
without
caus
cell
death
typic
milliand
microsecond
puls
use
ep
addit
increas
permeabl
target
cell
ep
may
also
enhanc
immun
respons
increas
protein
express
secret
inflammatori
chemokin
cytokin
recruit
apc
ep
site
result
antigenspecif
humor
cellular
immun
respons
ep
mediat
deliveri
plasmid
dna
higher
level
achiev
intramuscular
inject
dna
alon
inde
addit
vivo
ep
associ
consist
enhanc
cellmedi
humor
immun
respons
small
larg
anim
support
use
human
sever
devic
avail
vivo
dnaep
advanc
technolog
develop
inovio
pharmaceut
advanc
dnaep
cancer
vaccin
product
clinic
develop
tm
current
phase
ii
develop
cervic
displasiacanc
inovio
vaccin
includ
plasmid
encod
protein
hpv
type
intramuscular
inject
plasmid
dna
vaccin
follow
electropor
use
cellectra
deliv
devic
phase
dose
escal
studi
achiev
bestinclass
immun
respons
studi
treat
subject
histori
surgic
treat
vaccin
subject
develop
signific
tcell
respons
posit
respons
rang
spot
form
unit
sfu
per
million
cell
third
highest
dose
group
strong
tcell
respons
addit
vaccin
subject
develop
antibodi
respons
least
one
antigen
subject
develop
respons
two
antigen
dna
vaccin
previous
achiev
rate
respons
therapi
toler
signific
advers
event
cancer
vaccin
candid
pursu
inovio
dna
vaccin
develop
partnership
merck
design
target
cancer
express
antigen
andor
cea
id
b
dna
plasmid
also
develop
partnership
merck
encod
human
telomeras
htert
id
vaccin
deliv
phase
studi
use
medpuls
dna
deliveri
system
combin
ad
vector
c
leukemia
vaccin
target
deliv
use
inovio
autom
devic
dna
vaccin
offer
great
promis
also
present
ampl
margin
improv
efficaci
henc
sever
attempt
made
enhanc
immunogen
dna
vaccin
interestingli
case
enhanc
increment
use
dnaep
promis
avenu
use
codonoptim
b
gener
fusion
product
immunoenhanc
protein
c
codeliveri
gene
rnai
molecul
tlr
agonist
affect
immunoregulatori
signal
pathway
first
approach
aim
enhanc
express
encod
antigen
eukaryot
cell
transduc
vivo
well
known
elev
percentag
au
eukaryot
mrna
result
instabl
increas
turnov
low
express
level
encod
protein
furthermor
select
play
major
role
determin
codon
usag
organ
studi
far
matter
fact
highli
express
gene
narrow
set
codon
use
codon
correspond
abund
trna
speci
minim
risk
trna
deplet
translat
contrast
codon
rare
trna
gene
may
true
bottleneck
case
shown
substitut
rare
codon
may
increas
yield
dramat
simpl
algorithm
creat
therefor
design
codon
optim
cdna
shown
optim
codon
usag
sever
taa
gene
varieti
experiment
system
lead
signific
enhanc
express
increas
immunogen
second
approach
consist
creation
dna
vaccin
contain
tumor
antigen
sequenc
fuse
gene
often
exclus
microbi
gene
fuse
microbi
protein
engag
local
cell
provid
help
antitumor
immun
induc
potent
cell
respons
abl
suppress
tumor
growth
among
studi
fusion
dna
vaccin
incorpor
tumorderiv
sequenc
fuse
engin
domain
tetanu
toxin
b
subunit
heatlabil
enterotoxin
ecoli
third
final
approach
direct
simultan
potenti
activ
pathway
respons
induct
immun
respons
tumor
antigen
shown
exampl
possibl
deliv
tlr
agonist
also
use
interf
rna
target
apoptot
gene
last
case
believ
enhanc
immun
respons
target
tumor
antigen
enhanc
protect
tumor
develop
consequ
inhibit
cell
death
transduc
cell
sustain
tumor
antigen
express
conclus
dna
vaccin
sever
potenti
advantag
peptid
recombin
viral
vaccin
simpler
cheaper
produc
dna
immun
associ
anamnest
immun
respons
vector
instead
respons
inactiv
viral
vector
repeat
inject
hand
efficaci
requir
improv
especi
cancer
vaccin
target
self
antigen
immunolog
toler
may
block
function
emerg
evid
vaccin
schedul
compris
one
deliveri
method
antigen
ie
genet
vector
genet
vectorprotein
genet
vectorpeptid
etc
best
posit
overcom
therapeut
immun
threshold
adequ
har
immun
system
fight
cancer
exampl
sequenti
administr
plasmid
dna
adenovir
vector
differ
combin
may
result
synergist
immun
activ
inde
shown
preclin
murin
primat
model
heterolog
primeboost
regimen
induc
higher
frequenc
cell
nake
dna
recombin
viral
vector
alon
advantag
heterolog
primeboost
protocol
compris
sequenti
use
ad
plasmid
dna
one
exploit
strong
immunogen
ad
best
prime
agent
break
toler
dna
use
repeat
boost
lack
anamnest
respons
vector
recent
demonstr
ad
primedna
boost
vaccin
approach
direct
dog
telomeras
abl
give
rise
signific
increas
surviv
dog
affect
malign
lymphoma
anoth
approach
util
develop
prostvacvf
sequenti
administr
two
differ
viral
vector
carri
tumour
antigen
gene
also
bypass
limit
develop
neutral
antibodi
viral
backbon
boost
differ
vector
without
share
viral
epitop
cancer
immunotherapi
initi
advoc
specif
cancer
cell
fewer
side
effect
convent
therapi
concept
confirm
report
cancer
vaccin
clinic
trial
case
patient
experienc
complet
respons
absenc
seriou
advers
event
even
signific
exampl
benign
toxic
profil
sipuleucelt
point
howev
examin
larg
trial
vaccinerel
advers
event
albeit
rare
usual
mild
observ
exampl
recent
metaanalysi
case
advanc
cancer
patient
treat
therapeut
peptid
vaccin
sever
advers
event
sae
relat
vaccin
consist
mainli
local
skin
reaction
cellul
around
inject
site
case
system
effect
edema
head
neck
region
coliti
rectal
bleed
bladdervagin
fistula
report
occurr
autoimmun
particularli
evid
case
therapi
system
immunomodul
cancer
vaccin
inde
immunerel
advers
event
ira
commonli
observ
patient
blockad
like
reflect
drug
mechan
action
correspond
effect
immun
system
immunotox
result
ipilimumab
treatment
rang
rel
minor
condit
skin
depigment
sever
toxic
crucial
organ
system
liver
heart
lung
ipilimumab
registr
trial
grade
ira
occur
patient
treat
seven
death
associ
ira
treatmentrel
toxic
correl
better
respons
case
like
seriou
advers
event
immunemedi
reaction
increas
frequenc
sever
immunotherapeut
approach
becom
effect
henc
scientist
physician
guard
sae
associ
augment
immun
respons
strategi
develop
avoid
circumv
side
effect
use
viral
vector
past
genetherapi
trial
shown
caus
occurr
leukemogenesi
phenomenon
associ
use
retrovir
vector
due
integr
host
genom
activ
adjac
protooncogen
therefor
import
care
analyz
whether
genet
vaccin
make
use
either
nake
dna
viral
vector
may
rais
similar
issu
point
howev
genet
cancer
vaccin
vector
develop
bear
two
signific
differ
compar
gene
therapi
retrovir
vector
first
electropor
dna
ad
pox
vector
use
cancer
vaccin
low
null
chromosom
integr
respect
host
genom
second
vaccin
inocul
peripher
site
bodi
dermal
tissu
skelet
muscl
mainli
compos
termin
differenti
mitot
quiescent
cell
rate
regulatori
agenc
requir
inclus
genom
integr
genotox
studi
new
genet
vaccin
part
document
includ
ind
file
signific
progress
knowledg
immun
system
develop
innov
vaccin
technolog
lead
us
believ
cancer
vaccin
bright
futur
within
next
ten
year
becom
establish
therapeut
modal
cancer
practic
demonstr
recent
licensur
proveng
therapi
prostat
cancer
men
oncept
tm
therapi
oral
melanoma
dog
success
strictli
depend
upon
respect
four
major
principl
list
use
well
establish
vaccin
technolog
capabl
induc
strong
multiepitop
antigenspecif
b
cell
respons
use
reproduc
easili
scalabl
technolog
respect
believ
promis
technolog
base
use
genet
vector
ad
electropor
dna
primarili
use
heterolog
primeboost
combin
appropri
combin
vaccin
chemotherapi
andor
immunomodul
develop
articul
biomark
strategi
parallel
clinic
develop
standard
quantif
antigenspecif
cell
respons
pharmacodynam
measur
vaccin
immunogen
preselect
best
respond
treatment
develop
paradigm
take
account
evolv
scenario
draw
inspir
consist
improv
endpoint
cancer
immunotherapi
trial
author
declar
conflict
interest
